Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954631 | 0.86 | KMT2A (0.68) | KMT2AL3MBTL1NPSR1ALDH1A1MEN1 | |
| SCHEMBL5657811 | 0.85 | GAA (0.60) | KMT2AL3MBTL1ALDH1A1MEN1POLB | |
| SCHEMBL5656282 | 0.85 | KMT2A (0.67) | KMT2AL3MBTL1NPSR1ALDH1A1MEN1 | |
| SCHEMBL21059189 | 0.84 | SMN1; SMN2 (0.68) | KMT2AL3MBTL1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10893778 | 0.83 | KMT2A (0.72) | KMT2AL3MBTL1NPSR1ALDH1A1MEN1 | |
| SCHEMBL21059187 | 0.82 | L3MBTL1 (0.63) | KMT2AL3MBTL1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21059246 | 0.81 | L3MBTL1 (0.62) | KMT2AL3MBTL1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13032945 | 0.80 | KMT2A (0.60) | KMT2AL3MBTL1NPSR1ALDH1A1MEN1 | |
| SCHEMBL514089 | 0.80 | KMT2A (0.68) | KMT2AL3MBTL1ALDH1A1MEN1POLB | |
| SCHEMBL9191016 | 0.78 | ALDH1A1 (0.65) | KMT2AL3MBTL1NPSR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
| EP-1362041-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | Cerep (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068399-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | CEREP (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | KMT2A 2124/4885L3MBTL1 4733/4885NPSR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.